Estradiol is the gold standard for hormone replacement — but how it’s delivered to your body is just as important as the hormone itself. Different delivery methods produce different blood-level patterns, carry different risk profiles, target different tissues, and fit different lifestyles.
Luvo’s hormone replacement program offers five distinct estradiol formulations — more than most competitors provide. This comprehensive comparison helps you understand how each works, what it’s best for, and how they can be combined for complete symptom management.
Three of Luvo’s estradiol options provide systemic delivery — meaning the estradiol enters your bloodstream and circulates throughout your body, reaching estrogen receptors in the brain, bones, cardiovascular system, and other tissues.
Estradiol tablets are taken orally once daily. The hormone is absorbed through the GI tract and undergoes first-pass liver metabolism. This hepatic processing increases the production of certain liver proteins, including clotting factors and SHBG. The advantages are simplicity and familiarity. The clinical consideration is a modestly increased risk of venous thromboembolism compared to transdermal delivery.
Estradiol cream is applied to the skin daily. It absorbs through the dermis directly into the bloodstream, bypassing the liver. This avoids the clotting factor increase associated with oral delivery. The cream offers flexible dosing and a safe thrombotic profile. The practical trade-off is a brief daily application routine.
Estradiol patches are applied to the skin and replaced once or twice weekly. Like cream, they deliver estradiol transdermally. The unique advantage of patches is exceptionally steady hormone levels — no daily peaks and troughs. They offer the most consistent delivery, the best thrombotic safety, and the lowest maintenance routine of any systemic option.
Two of Luvo’s estradiol options deliver the hormone directly to the vaginal and urogenital tissues, with minimal absorption into the systemic circulation.
Estradiol vaginal gel is applied intravaginally using a measured applicator. It distributes across the vaginal walls and provides concentrated estrogen to the tissue that needs it most. Vaginal gel is effective for treating vaginal dryness, painful intercourse, vaginal atrophy, and urinary symptoms.
Estradiol vaginal tablets are small tablets inserted vaginally. They dissolve in place and release estradiol locally. The tablet format is clean, precise, and mess-free. Like the gel, it effectively treats GSM symptoms.
Both vaginal formulations produce very low systemic estradiol levels — typically remaining within the normal postmenopausal range. This makes them appropriate for women who need localized therapy but want to avoid or minimize systemic estrogen exposure.
Many women benefit from using more than one estradiol formulation simultaneously. This isn’t over-treatment — it’s targeted treatment.
The most common combination is a systemic formulation (tablets, cream, or patches) for hot flashes, mood, sleep, and bone protection, plus a vaginal formulation (gel or tablets) for concentrated urogenital symptom relief. Systemic estradiol provides some benefit to vaginal tissues, but many women find it insufficient for significant GSM symptoms. Adding vaginal estradiol provides the concentrated local effect these tissues need.
Your Luvo provider designs the combination based on your specific symptom profile. A woman whose primary complaints are hot flashes and insomnia might start with patches alone. If vaginal dryness develops later, vaginal gel or tablets can be added without changing the systemic component.
This modular approach — building and adjusting a multi-formulation protocol over time — is one of the key advantages of Luvo’s 10-medication program.
Here’s a practical summary to aid your decision.
Estradiol tablets are best for women who want simple daily dosing and have no elevated clotting risk. Application is a daily pill with no skin considerations. They offer the most straightforward routine but do carry modestly elevated thrombotic risk.
Estradiol cream is best for women wanting transdermal safety with flexible dosing. Application is daily to the skin with a brief drying period. It offers good safety and dose adjustability.
Estradiol patches are best for women wanting the steadiest levels and lowest maintenance. Application is once or twice weekly to the skin. They offer the most consistent delivery and best thrombotic safety.
Estradiol vaginal gel is best for vaginal dryness and urogenital symptoms. Application is intravaginal with an applicator. It provides excellent localized therapy with minimal systemic absorption.
Estradiol vaginal tablets are best for the same symptoms as gel with a cleaner, more precise format. Application is a small tablet inserted vaginally. It provides the same targeted relief with less mess.
Explore each option in detail: estradiol tablets, estradiol cream, estradiol patches, estradiol vaginal gel, and estradiol vaginal tablets. Or visit Luvo’s hormone replacement program for a comprehensive evaluation.
If your understanding of hormone replacement therapy is shaped by headlines from 20 years ago, it’s time for an update. The 2002 Women’s Health Initiative (WHI) study sent shockwaves through medicine, leading millions of women to abandon HRT and a generation of physicians to stop prescribing it. But the decades since have brought dramatic clarity: the WHI’s findings were widely misinterpreted, and the resulting fear of HRT caused immeasurable harm to women who could have benefited from treatment.
Today, major medical organizations including the North American Menopause Society, the Endocrine Society, and the American College of Obstetricians and Gynecologists affirm that HRT is safe and effective for most women experiencing menopause symptoms, particularly when started within 10 years of menopause onset.
Luvo’s hormone replacement program is built on this modern evidence base. With 10 medication options spanning estradiol formulations, testosterone therapy, and non-hormonal alternatives, it offers a level of treatment personalization that most competitors simply can’t match.
Menopause isn’t a single event — it’s a transition that typically spans several years. The process begins in perimenopause, usually in the mid-40s, when the ovaries begin producing less estrogen and progesterone. Hormone levels fluctuate unpredictably, causing symptoms that can range from mildly annoying to severely disruptive.
Menopause is officially reached when 12 consecutive months pass without a menstrual period, typically around age 51. At this point, the ovaries have largely ceased producing estrogen, and levels of this hormone remain permanently low.
Estrogen isn’t just a reproductive hormone. It has receptors throughout the body — in the brain, bones, cardiovascular system, urogenital tract, skin, and joints. When estrogen declines, the effects cascade across multiple systems: vasomotor symptoms like hot flashes and night sweats, sleep disruption, mood changes and cognitive fog, vaginal dryness and urogenital atrophy, bone density loss, cardiovascular risk changes, joint pain and muscle loss, and skin and hair changes.
Testosterone also declines in women, though more gradually. By menopause, a woman’s testosterone level may be half what it was in her 20s, contributing to decreased libido, reduced energy, and loss of muscle mass.
HRT addresses these declines by restoring hormones to levels that alleviate symptoms and protect long-term health.
What sets Luvo apart from competitors like Hims, Willow, or Pomegranate is the breadth of our medication options. Managing hormonal decline isn’t one-size-fits-all, and neither is our program.
Estradiol is available in five formulations: oral tablets for systemic hormone delivery, transdermal cream for absorption through the skin, transdermal patches for steady-state hormone levels, vaginal gel for localized urogenital symptom relief, and vaginal tablets for targeted vaginal atrophy treatment.
Testosterone for women is available in three formulations: injection, oral tablets, and topical gel — addressing the often-overlooked role of testosterone in female vitality, libido, and body composition.
Non-hormonal options include Paroxetine, the only FDA-approved non-hormonal treatment for vasomotor symptoms, and Desvenlafaxine, an SNRI with strong evidence for hot flash reduction. These serve women who cannot or prefer not to use hormonal therapy.
This 10-medication toolkit means your Luvo provider can design a protocol precisely matched to your symptoms, health history, preferences, and risk profile.
HRT is most clearly indicated for women experiencing moderate to severe vasomotor symptoms such as hot flashes and night sweats, women under 60 or within 10 years of menopause onset (the “window of opportunity” for cardiovascular and bone benefits), women with premature ovarian insufficiency or early menopause (before age 40), women with significant urogenital symptoms like vaginal dryness, painful intercourse, or recurrent UTIs, and women at elevated risk for osteoporosis.
HRT may require additional evaluation or alternatives for women with a history of breast cancer, women with active cardiovascular disease or a history of blood clots, women with undiagnosed vaginal bleeding, and women with active liver disease.
Luvo’s providers conduct thorough health evaluations to determine the safest and most effective approach for each patient. For women who cannot use estrogen, our non-hormonal options provide meaningful symptom relief.
Explore Luvo’s full hormone replacement program to learn more.
Of all the symptoms of menopause, vaginal and urogenital changes may be the most underreported and undertreated. Up to 80% of postmenopausal women experience genitourinary syndrome of menopause (GSM) — a term that encompasses vaginal dryness, burning, irritation, painful intercourse (dyspareunia), urinary urgency and frequency, and recurrent urinary tract infections.
Unlike hot flashes, which often improve over time, GSM is progressive. Without treatment, it gets worse with each passing year as the estrogen-dependent tissues of the vagina and urinary tract continue to thin, lose elasticity, and become increasingly fragile.
The good news: localized vaginal estradiol is one of the most effective, safest, and most well-tolerated treatments in all of HRT. Luvo offers two vaginal estradiol formulations — vaginal gel and vaginal tablets — specifically for this purpose.
GSM occurs because the vaginal and urethral tissues are highly estrogen-dependent. When estrogen levels drop during and after menopause, these tissues undergo significant changes.
The vaginal epithelium thins from multiple cell layers to just a few, becoming fragile and easily irritated. Vaginal pH rises from its normal acidic range (3.5–4.5) to neutral or alkaline levels, disrupting the protective microbial environment and increasing susceptibility to infections. Blood flow to the vaginal and urethral tissues decreases, reducing natural lubrication and tissue health. The vaginal walls lose elasticity and may actually narrow and shorten. The urethral lining thins, contributing to urinary symptoms.
These changes can profoundly affect quality of life and intimate relationships. Many women avoid sexual activity entirely because of pain, and urinary symptoms can restrict daily activities. Yet studies consistently show that fewer than 25% of affected women receive treatment — often because they don’t mention symptoms to their provider, or their provider doesn’t ask.
Vaginal estradiol delivers the hormone directly to the tissues that need it most. Unlike systemic estradiol (tablets, cream, or patches), vaginal formulations are designed for localized action with minimal absorption into the bloodstream.
When applied vaginally, estradiol is absorbed by the estrogen-receptor-rich cells of the vaginal epithelium. It stimulates cell proliferation and maturation, restoring the vaginal lining to a healthier, more resilient state. Vaginal pH normalizes, protective lactobacilli return, lubrication improves, and the tissue regains elasticity and blood flow.
The systemic absorption of vaginal estradiol is very low — significantly lower than oral or transdermal estradiol. Blood estradiol levels with vaginal formulations typically remain within the normal postmenopausal range. This is why vaginal estradiol is considered safe for many women who cannot use systemic HRT, including some breast cancer survivors (though this should always be discussed with an oncologist).
Luvo offers two formulations for localized estradiol delivery.
Estradiol vaginal gel is applied intravaginally using a pre-measured applicator. The gel distributes evenly across the vaginal walls, providing broad tissue contact. Many women find the gel comfortable and easy to use. Application is typically daily for the initial treatment period, then reduced to a maintenance schedule of 2–3 times per week. The gel formulation can also provide some benefit to the external vulvar area during application.
Estradiol vaginal tablets are small tablets inserted into the vagina using a disposable applicator. They dissolve and release estradiol locally. The tablet format is clean, mess-free, and appeals to women who prefer a solid formulation over a gel. Like the gel, initial treatment is usually daily, transitioning to a maintenance schedule.
Both formulations are effective for treating vaginal dryness, painful intercourse, vaginal atrophy, and urinary symptoms. The choice between them often comes down to personal preference and comfort.
Explore Luvo’s estradiol vaginal gel and estradiol vaginal tablets.
Understanding whether you need localized therapy, systemic therapy, or both is an important conversation to have with your Luvo provider.
Vaginal estradiol alone is appropriate if your primary symptoms are urogenital — vaginal dryness, painful sex, urinary issues — and you don’t have significant hot flashes, sleep disruption, or other systemic symptoms. It’s also a good option for women who have contraindications to systemic estrogen or prefer to avoid it.
Systemic estradiol (tablets, cream, or patches) is needed if you have systemic symptoms like hot flashes, night sweats, mood changes, or bone density concerns. Systemic therapy also provides some benefit to vaginal tissues, though many women find that adding localized vaginal estradiol provides more complete urogenital relief.
Combination therapy — systemic plus vaginal — is appropriate for women who have both systemic and significant urogenital symptoms. The systemic dose is set for overall symptom management, while vaginal estradiol provides the concentrated local effect the vaginal tissues need.
Luvo’s program supports all three approaches, and your provider will recommend the strategy that best addresses your symptom profile. Visit the hormone replacement program page to get started.
No two women experience menopause the same way. Some are primarily bothered by hot flashes. Others struggle most with vaginal dryness or painful sex. Some are blindsided by mood changes and cognitive fog. And many deal with multiple symptoms simultaneously, each requiring its own treatment consideration.
The problem with one-size-fits-all HRT programs is that they treat menopause as a single condition with a single solution. Luvo’s program takes a symptom-specific approach, matching treatments to what you’re actually experiencing. This guide maps common menopause symptoms to the Luvo medications most effective for each.
Vasomotor symptoms are the hallmark of menopause, affecting up to 80% of women. They’re caused by estrogen-withdrawal-driven instability in the hypothalamic thermoregulatory center.
First-line treatments from Luvo include systemic estradiol, which directly addresses the underlying estrogen deficit. Estradiol tablets, cream, or patches all effectively reduce hot flash frequency and severity, typically by 75–95%. Transdermal options (cream and patches) are preferred for women with clotting risk factors.
For women who cannot take estrogen, Paroxetine is the FDA-approved non-hormonal option, reducing hot flash frequency by 33–65%. Desvenlafaxine offers potentially greater reduction at 55–70% and the added benefit of norepinephrine activity for energy and mood.
Night sweats are essentially nocturnal hot flashes and respond to the same treatments. Because they disrupt sleep, addressing them often produces cascading improvements in daytime energy, mood, and cognitive function.
Genitourinary syndrome of menopause (GSM) is progressive and affects the majority of postmenopausal women.
Localized vaginal estradiol is the most direct and effective treatment. Luvo’s estradiol vaginal gel and vaginal tablets deliver estrogen directly to the affected tissues with minimal systemic absorption. Most women experience significant improvement within 2–4 weeks, with continued improvement over 3 months.
Systemic estradiol (tablets, cream, or patches) provides some vaginal benefit as well, but many women with GSM need the additional concentrated local therapy that vaginal formulations provide.
For women who cannot use any form of estrogen, regular use of vaginal moisturizers and lubricants combined with Paroxetine or Desvenlafaxine for any accompanying vasomotor symptoms is the recommended alternative approach.
Declining sexual desire is one of the most distressing menopause symptoms and one of the most undertreated. It has both estrogen and testosterone components.
Testosterone therapy is the most evidence-based treatment for hypoactive sexual desire in postmenopausal women. Luvo’s testosterone injection, tablets, or gel can be added to an estradiol regimen (or used alone) to address libido directly. The 2019 Lancet meta-analysis confirmed that testosterone significantly improves desire, arousal, orgasm, and satisfaction in postmenopausal women.
Estradiol addresses the physical component by improving vaginal health, lubrication, and comfort during intercourse. When sex is no longer painful (thanks to vaginal estradiol), desire often improves as well.
The combination of systemic estradiol plus vaginal estradiol plus testosterone addresses sexual dysfunction from every angle — hormonal drive, physical comfort, and tissue health. This comprehensive approach is one of Luvo’s key differentiators.
Mood symptoms during menopause are driven by multiple factors: estrogen’s effects on serotonin and other neurotransmitters, sleep disruption from night sweats, and the psychological impact of the transition itself.
Estradiol therapy often produces significant mood improvement, particularly when mood symptoms are clearly linked to the menopausal transition. Stabilizing estrogen levels helps stabilize the neurochemical environment.
Paroxetine and Desvenlafaxine address mood symptoms through direct serotonergic and noradrenergic mechanisms. For women whose mood symptoms are severe, these medications may be used alongside or instead of estradiol. Desvenlafaxine’s SNRI mechanism may be particularly effective for the combination of depression, fatigue, and hot flashes.
Testosterone can contribute to improved mood, confidence, and overall sense of well-being. It’s rarely used as a primary mood treatment but can provide meaningful benefit as part of a comprehensive protocol.
Cognitive changes, persistent fatigue, and loss of lean mass are increasingly recognized as significant menopause symptoms driven by both estrogen and testosterone decline.
Estradiol supports cognitive function through its effects on cerebral blood flow, synaptic plasticity, and neurotransmitter function. Many women report improved mental clarity within weeks of starting estradiol therapy.
Testosterone’s role in energy, cognitive sharpness, and muscle maintenance makes it a valuable addition for women experiencing these symptoms. The anabolic effects of testosterone help maintain the lean mass and metabolic rate that decline during menopause.
Desvenlafaxine’s norepinephrine activity can address fatigue and cognitive fog independently of hormonal mechanisms, making it useful either as a complement to HRT or as a standalone option.
Luvo’s program recognizes that these symptoms often require a multi-medication strategy. Your provider will build a protocol that addresses your complete symptom picture. Visit the hormone replacement program to get started.